NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

Published Date: 22 May 2026

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Read Full News

Latest News

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Latest News

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

News All Time

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Recommended News For You

Chromatin organization linked to p53 tumor suppression mechanism

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

There has been a new target found that might stop blood cancer.

Clinical trial sees dramatic results using radiation to treat breast cancer

An effective treatment for a rare but deadly form of cancer

Who Bears the Cost of "Forever Chemical" Cleanup?

Recommended Articles For You

Unlocking the Mystery of Ovarian Cancer Staging 

Integrative Clinical Genomics of Metastatic Cancer: Decoding Tumor Evolution for Precision Oncology 

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Rural-urban disparities seen in cervical cancer

2.

When does a melanoma metastasize? Implications for management

3.

Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT

4.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

5.

New Immune Therapy Boosts Disease Control in Prostate Cancer

1.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

2.

ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection

3.

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure 

4.

Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence

5.

Segmental vs. Non-Segmental Vitiligo: What’s the Difference?

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Updates on Standard V/S High Risk Myeloma Treatment

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

3.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot